Annual CFO
-$19.78 M
+$8.22 M+29.35%
30 September 2023
Summary:
ESSA Pharma annual cash flow from operations is currently -$19.78 million, with the most recent change of +$8.22 million (+29.35%) on 30 September 2023. During the last 3 years, it has risen by +$5.63 million (+22.17%). EPIX annual CFO is now -850.49% below its all-time high of -$2.08 million, reached on 30 September 2014.EPIX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$5.75 M
+$1.07 M+15.74%
30 June 2024
Summary:
ESSA Pharma quarterly cash flow from operations is currently -$5.75 million, with the most recent change of +$1.07 million (+15.74%) on 30 June 2024. Over the past year, it has dropped by -$1.26 million (-28.00%). EPIX quarterly CFO is now -73755.13% below its all-time high of $7800.00, reached on 31 March 2014.EPIX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$23.84 M
-$839.50 K-3.65%
30 June 2024
Summary:
ESSA Pharma TTM cash flow from operations is currently -$23.84 million, with the most recent change of -$839.50 thousand (-3.65%) on 30 June 2024. Over the past year, it has dropped by -$4.06 million (-20.51%). EPIX TTM CFO is now -22932.37% below its all-time high of -$103.50 thousand, reached on 31 March 2014.EPIX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
EPIX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -28.0% | -20.5% |
| 3 y3 years | +22.2% | +22.2% | +6.2% |
| 5 y5 years | -61.5% | -11.5% | -94.6% |
EPIX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +29.4% | -31.3% | +31.5% | -20.5% | +15.2% |
| 5 y | 5 years | -61.5% | +29.4% | -71.0% | +31.5% | -94.6% | +15.2% |
| alltime | all time | -850.5% | +29.4% | <-9999.0% | +31.5% | <-9999.0% | +15.2% |
ESSA Pharma Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | -$5.75 M(-15.7%) | -$23.84 M(+3.7%) |
| Mar 2024 | - | -$6.82 M(+0.5%) | -$23.00 M(+3.6%) |
| Dec 2023 | - | -$6.79 M(+51.2%) | -$22.19 M(+12.2%) |
| Sept 2023 | -$19.78 M(-29.3%) | -$4.49 M(-8.5%) | -$19.78 M(-13.1%) |
| June 2023 | - | -$4.91 M(-18.4%) | -$22.77 M(-5.8%) |
| Mar 2023 | - | -$6.01 M(+37.3%) | -$24.18 M(-8.9%) |
| Dec 2022 | - | -$4.38 M(-41.5%) | -$26.56 M(-5.2%) |
| Sept 2022 | -$28.00 M(+10.2%) | -$7.48 M(+18.4%) | -$28.00 M(+0.3%) |
| June 2022 | - | -$6.32 M(-24.7%) | -$27.91 M(-0.7%) |
| Mar 2022 | - | -$8.39 M(+44.1%) | -$28.11 M(+3.0%) |
| Dec 2021 | - | -$5.82 M(-21.2%) | -$27.29 M(+7.4%) |
| Sept 2021 | -$25.42 M(+49.7%) | -$7.38 M(+13.3%) | -$25.42 M(+14.6%) |
| June 2021 | - | -$6.52 M(-13.9%) | -$22.18 M(+15.8%) |
| Mar 2021 | - | -$7.57 M(+92.1%) | -$19.15 M(+9.0%) |
| Dec 2020 | - | -$3.94 M(-5.0%) | -$17.57 M(+3.4%) |
| Sept 2020 | -$16.98 M(+38.6%) | -$4.15 M(+19.0%) | -$16.98 M(-5.6%) |
| June 2020 | - | -$3.49 M(-41.7%) | -$17.98 M(+5.9%) |
| Mar 2020 | - | -$5.98 M(+78.1%) | -$16.99 M(+23.5%) |
| Dec 2019 | - | -$3.36 M(-34.8%) | -$13.76 M(+12.3%) |
| Sept 2019 | -$12.25 M | -$5.15 M(+106.5%) | -$12.25 M(+31.3%) |
| June 2019 | - | -$2.49 M(-9.5%) | -$9.33 M(-3.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2019 | - | -$2.75 M(+48.9%) | -$9.65 M(-4.7%) |
| Dec 2018 | - | -$1.85 M(-17.1%) | -$10.13 M(-0.9%) |
| Sept 2018 | -$10.22 M(-41.1%) | -$2.23 M(-20.4%) | -$10.22 M(-7.1%) |
| June 2018 | - | -$2.81 M(-13.3%) | -$11.00 M(-17.1%) |
| Mar 2018 | - | -$3.24 M(+66.5%) | -$13.27 M(+4.1%) |
| Dec 2017 | - | -$1.94 M(-35.6%) | -$12.74 M(-26.6%) |
| Sept 2017 | -$17.35 M(+13.4%) | -$3.02 M(-40.6%) | -$17.35 M(-2.1%) |
| June 2017 | - | -$5.08 M(+87.5%) | -$17.73 M(+10.5%) |
| Mar 2017 | - | -$2.71 M(-58.7%) | -$16.05 M(-16.7%) |
| Dec 2016 | - | -$6.55 M(+93.1%) | -$19.25 M(+25.8%) |
| Sept 2016 | -$15.30 M(+14.7%) | -$3.39 M(+0.1%) | -$15.30 M(-8.3%) |
| June 2016 | - | -$3.39 M(-42.7%) | -$16.69 M(-9.0%) |
| Mar 2016 | - | -$5.92 M(+127.4%) | -$18.34 M(+32.2%) |
| Dec 2015 | - | -$2.60 M(-45.6%) | -$13.87 M(+4.0%) |
| Sept 2015 | -$13.34 M(+541.0%) | -$4.78 M(-5.0%) | -$13.34 M(+36.0%) |
| June 2015 | - | -$5.03 M(+246.3%) | -$9.81 M(+78.4%) |
| Mar 2015 | - | -$1.45 M(-29.7%) | -$5.50 M(+36.2%) |
| Dec 2014 | - | -$2.07 M(+65.0%) | -$4.04 M(+94.0%) |
| Sept 2014 | -$2.08 M | -$1.25 M(+72.8%) | -$2.08 M(+151.2%) |
| June 2014 | - | -$725.00 K(-9394.9%) | -$828.50 K(+700.5%) |
| Mar 2014 | - | $7800.00(-107.0%) | -$103.50 K(-7.0%) |
| Dec 2013 | - | -$111.30 K | -$111.30 K |
FAQ
- What is ESSA Pharma annual cash flow from operations?
- What is the all time high annual CFO for ESSA Pharma?
- What is ESSA Pharma quarterly cash flow from operations?
- What is the all time high quarterly CFO for ESSA Pharma?
- What is ESSA Pharma quarterly CFO year-on-year change?
- What is ESSA Pharma TTM cash flow from operations?
- What is the all time high TTM CFO for ESSA Pharma?
- What is ESSA Pharma TTM CFO year-on-year change?
What is ESSA Pharma annual cash flow from operations?
The current annual CFO of EPIX is -$19.78 M
What is the all time high annual CFO for ESSA Pharma?
ESSA Pharma all-time high annual cash flow from operations is -$2.08 M
What is ESSA Pharma quarterly cash flow from operations?
The current quarterly CFO of EPIX is -$5.75 M
What is the all time high quarterly CFO for ESSA Pharma?
ESSA Pharma all-time high quarterly cash flow from operations is $7800.00
What is ESSA Pharma quarterly CFO year-on-year change?
Over the past year, EPIX quarterly cash flow from operations has changed by -$1.26 M (-28.00%)
What is ESSA Pharma TTM cash flow from operations?
The current TTM CFO of EPIX is -$23.84 M
What is the all time high TTM CFO for ESSA Pharma?
ESSA Pharma all-time high TTM cash flow from operations is -$103.50 K
What is ESSA Pharma TTM CFO year-on-year change?
Over the past year, EPIX TTM cash flow from operations has changed by -$4.06 M (-20.51%)